Upregulating serotonin transporter expression and downregulating monoamine oxidase-A and indoleamine 2, 3-dioxygenase expression involved in the antidepressant effect of sodium valproate in a rat model

NeuroReport

Volumn 25, Issue 17, 2014, Pages 1338-1343

  Qiu, Hong Mei ^a   Yang, Jun Xia ^a   Jiang, Xin Hui ^a   Fei, Hui Zhi ^a   Liu, Dan ^a   Hu, Xiao Ya ^a   Zhou, Qi Xin ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

3 dioxygenase; Indoleamine 2; Monoamine oxidase A; Serotonin transporter; Sodium valproate; Tryptophan hydroxylase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; INDOLEAMINE 2,3 DIOXYGENASE; SEROTONIN; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; VALPROIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; MESSENGER RNA; SLC6A4 PROTEIN, RAT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC UNPREDICTED STRESS; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DOWN REGULATION; DRUG MECHANISM; FORCED SWIM TEST; HIPPOCAMPUS; HYPERACTIVITY; MALE; NONHUMAN; OPEN FIELD TEST; PRESYNAPTIC NERVE; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; STRESS; UPREGULATION; ANIMAL; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MONOAMINE OXIDASE; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRESS, PSYCHOLOGICAL; TRYPTOPHAN HYDROXYLASE; VALPROIC ACID;

EID: 84916925495     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000269     Document Type: Article

References (25)

1. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013; 34:119-138.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349:1436-1442.
3. Hepgul N, Cattaneo A, Zunszain PA, Pariante CM. Depression pathogenesis and treatment: What can we learn from blood mRNA expression? BMC Med 2013; 11:28.
4. Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 2003; 64 (Suppl 13):26-29.
5. Kim SW, Park SY, Hwang O. Up-regulation of tryptophan hydro xylase expression and serotonin synthesis by sertra line. Mol Pharmacol 2002; 61:778-785.
6. Schulze TG, Müller DJ, Krauss H, Scherk H, Ohlraun S, Syagailo YV, et al. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet 2000; 96:801-803.
7. Thase ME. The role of monoamine oxidase inhibitors in depression treatment guidelines. J Clin Psychiatry 2012; 73:10-16.
8. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009; 2:1-19.
9. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new 5'-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro psychopharmacol Biol Psychiatry 2011; 35:702-721.
10. Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL. Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis. J Affect Disord 2010; 122 (1-2):1-9.
11. Haddad PM, Das A, Ashfaq M, Wieck A. A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 2009; 5:539-551.
12. Monti B, Polazzi E, Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuro protection. Curr Mol Pharmacol 2009; 2:95-109.
13. Qiu HM, Yang JX, Liu D, Fei HZ, Hu XY, Zhou QX. Anti depressive effect of sodium valproate involving suppression of corticotropin-releasing factor expression and elevation of BDNF expression in rats exposed to chronic unpredicted stress. Neuro report 2014; 25:205-210.
14. Molina VA, Volosin M, Cancela L, Keller E, Murúa VS, Basso AM. Effect of chronic variable stress on monoamine receptors: Influence of imipramine administration. Pharmacol Biochem Behav 1990; 35:335-340.
15. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: A new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47:379-391.
16. Chen L, Chen M, Wang F, Sun Z, Quanzhi H, Geng M, et al. Anti depressant like effects of shuyusan in rats exposed to chronic stress: effects on hypothalamic-pituitary-adrenal function. Evid Based Complement Alternat Med 2012; 2012:[Epub ahead of print].
17. Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. Behav Pharmacol 2002; 13:169-188.
18. Brenes Sáenz JC, Villagra OR, Fornaguera Trías J. Factor analysis of forced swimming test, sucrose preference test and open field test on enriched, social and isolated reared rats. Behav Brain Res 2006; 169:57-65.
19. Mann JJ, Malone KM, Nielsen DA, Goldman D, Erdos J, Gelernter J. Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Am J Psychiatry 1997; 154:1451-1453.
20. Qiu HM, Yang JX, Wu XH, Li N, Liu D, Wang LJ, et al. Anti depressive effect of paroxetine in a rat model: upregulating expression of serotonin and nor epinephrine transporter. Neuro report 2013; 24:520-525.
21. Jiang X, Wang J, Luo T, Li Q. Impaired hypothalamic-pituitary-adrenal axis and its feedback regulation in serotonin transporter knockout mice. Psycho neuro endocrinology 2009; 34:317-331.
22. Perona MT, Waters S, Hall FS, Sora I, Lesch KP, Murphy DL, et al. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 2008; 19 (5-6):566-574.
23. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al. Elevated monoamine oxidase A levels in the brain: An explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006; 63:1209-1216.
24. Takikawa O. Biochemical and medical aspects of the indoleamine 2, 3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun 2005; 338:12-19.
25. O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the up regulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009; 29:4200-4209.